000302864 001__ 302864
000302864 005__ 20250720021506.0
000302864 0247_ $$2doi$$a10.1007/s00259-025-07427-4
000302864 0247_ $$2pmid$$apmid:40590903
000302864 0247_ $$2ISSN$$a1619-7070
000302864 0247_ $$2ISSN$$a1619-7089
000302864 0247_ $$2altmetric$$aaltmetric:178591554
000302864 037__ $$aDKFZ-2025-01404
000302864 041__ $$aEnglish
000302864 082__ $$a610
000302864 1001_ $$00000-0002-1476-6299$$aZitzmann-Kolbe, Sabine$$b0
000302864 245__ $$aBiodistribution of free Francium-221 and Bismuth-213 in Tumour-bearing SCID mice after successful development of Actinium-225/Francium-221 radionuclide generator Set-up.
000302864 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2025
000302864 3367_ $$2DRIVER$$aarticle
000302864 3367_ $$2DataCite$$aOutput Types/Journal article
000302864 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1752746656_14019
000302864 3367_ $$2BibTeX$$aARTICLE
000302864 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000302864 3367_ $$00$$2EndNote$$aJournal Article
000302864 500__ $$a#LA:E270# / epub
000302864 520__ $$aDespite the clinical evidence of actinium-225 (225Ac)-based targeted alpha therapies (TαT) efficacy, optimized treatment regimens are needed to improve overall clinical response rates and decrease toxicities. The nuclear recoil effect of 225Ac and its resulting daughter nuclides have been hypothesized to contribute to non-targeted damage. However, a lack of generator concepts for radionuclidically pure francium-221 (221Fr), involvement of strong acids for elution, and its short half-life (4.8 min), has limited in vivo studies. Here, we report on a successful application of an 225Ac/221Fr generator concept and the in vivo distribution of 221Fr and bismuth-213 (213Bi).The immobilization of 225Ac and elution of 221Fr was performed on a LN2 resin column. The biodistribution of 221Fr and 213Bi was investigated in male SCID mice with LNCaP tumors at 5 and 15 min p.i.Our results indicate that LN2 resin is a highly efficient resin for selective separation of 225Ac and 221Fr. The use of 0.1 M NaOAc enabled continuous elution at a constant pH. The biodistribution study revealed a fast distribution of 221Fr and 213Bi already 5 min p.i. We observed a strong accumulation of 221Fr to the kidneys, salivary glands and small intestine. In 213Bi-injected mice, the highest accumulation was in kidney and liver.We present an unprecedented concept utilizing LN2 resin in 225Ac/221Fr generator applications. Successfully eluted and injected 221Fr fractions showed strong accumulation of 221Fr and 213Bi in key organs. Our data provide preliminary evidence of the potential contribution of recoiled progeny radionuclides to side-effects in non-targeted organs.
000302864 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000302864 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000302864 650_7 $$2Other$$aActinium-225
000302864 650_7 $$2Other$$aBismuth-213
000302864 650_7 $$2Other$$aFrancium-221
000302864 650_7 $$2Other$$aRadionuclide generators
000302864 650_7 $$2Other$$aRadionuclide-specific organ accumulation
000302864 650_7 $$2Other$$aTargeted alpha therapies
000302864 7001_ $$0P:(DE-He78)7391d5b7c56f3a52656bfb12636b333f$$aRemde, Yvonne$$b1$$udkfz
000302864 7001_ $$00000-0001-9814-9644$$aMoen, Ingrid$$b2
000302864 7001_ $$00000-0002-0698-4982$$aMadas, Balázs$$b3
000302864 7001_ $$aMázik, László$$b4
000302864 7001_ $$aSuurs, Frans$$b5
000302864 7001_ $$00000-0003-3567-9415$$aHappel, Steffen$$b6
000302864 7001_ $$0P:(DE-He78)3373acf5d3b93adfd9ea973cf2d218aa$$aSchäfer, Martin$$b7$$udkfz
000302864 7001_ $$00000-0001-8017-3400$$aSchatz, Christoph$$b8
000302864 7001_ $$0P:(DE-He78)857dc4f13329fd151170f3e2b9edfba0$$aTas, Harun$$b9$$udkfz
000302864 7001_ $$00009-0003-6509-0844$$aHagemann, Urs B$$b10
000302864 7001_ $$0P:(DE-He78)0f034e05cefb010f991ef8b96009d95c$$aBenesova-Schäfer, Martina$$b11$$eLast author$$udkfz
000302864 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-025-07427-4$$pnn$$tEuropean journal of nuclear medicine and molecular imaging$$vnn$$x1619-7070$$y2025
000302864 909CO $$ooai:inrepo02.dkfz.de:302864$$pVDB
000302864 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7391d5b7c56f3a52656bfb12636b333f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000302864 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3373acf5d3b93adfd9ea973cf2d218aa$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000302864 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)857dc4f13329fd151170f3e2b9edfba0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000302864 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0f034e05cefb010f991ef8b96009d95c$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000302864 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000302864 9141_ $$y2025
000302864 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-05$$wger
000302864 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-05$$wger
000302864 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
000302864 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000302864 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000302864 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-05
000302864 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-05
000302864 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
000302864 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-05
000302864 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-05
000302864 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-05
000302864 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-05
000302864 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
000302864 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
000302864 9202_ $$0I:(DE-He78)E270-20160331$$kE270$$lTranslationale Radiotheranostik$$x0
000302864 9201_ $$0I:(DE-He78)W630-20160331$$kW630$$lRadiopharmazeutika und Präklinische Studien$$x0
000302864 9201_ $$0I:(DE-He78)E270-20160331$$kE270$$lTranslationale Radiotheranostik$$x1
000302864 980__ $$ajournal
000302864 980__ $$aVDB
000302864 980__ $$aI:(DE-He78)W630-20160331
000302864 980__ $$aI:(DE-He78)E270-20160331
000302864 980__ $$aUNRESTRICTED